MREO — Mereo BioPharma Share News
0.000.00%
Last trade - 00:00- $44.96m
- $14.85m
- $0.50m
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand
NASDAQ RESUMED AT 08:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
Mereo BioPharma Q3 net loss narrows aided by foreign currency gain
Brief: Mereo BioPharma Q3 Net Income USD -7.024 Million
Mereo BioPharma Group PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Mereo BioPharma Reports Second Quarter 2025 Financial Results And Provides Corporate Highlights
Ultragenyx, Mereo tumble after update on genetic disorder drug trial data
Mereo BioPharma Group PLC reports results for the quarter ended March 31 - Earnings Summary
Mereo BioPharma Group PLC expected to post a loss of 1 penny a share - Earnings Preview
Brief: Mereo BioPharma Reports Full Year 2024 Financial Results And Provides Corporate Highlights
Brief: Mereo Biopharma Group Files Prospectus For Offer, Resale By Selling Shareholders Of Up To 26.6 Mln Of Ordinary Shares In Form Of ADSS
Ultragenyx Pharma falls on stock offering pricing
Brief: Mereo Biopharma Announces Pricing Of $50 Million Underwritten Registered Direct Offering
Ultragenyx Pharma drops after launching $350 mln stock offering
Brief: Ultragenyx And Mereo Biopharma Announce New Phase 2 Data From Phase 2/3 Orbit Study Demonstrating Sustained Reductions In Fracture Rates Following Treatment With Setrusumab (Ux143) In Patients With Osteogenesis Imperfecta (Oi)